A previous study demonstrated that in vivo treatment with Tim-3 monoclonal antibodies during the induction of EAE, which is a mouse model of multiple sclerosis (MS), accelerated disease progression (11). This evidence concerns the gene HAVCR2 and myeloid sarcoma.